Laboratory Monitoring of New Hemostatic Agents for Hemophilia

Prophylactic infusion of factor replacement products results in a reduction in long-term morbidity and mortality in patients with severe hemophilia. The needed frequency of intravenous access is commonly through central venous access devices, however, which may result in complications such as infections and thrombosis. Available clinical data on extended half-life (EHL) factor replacement products indicates a potential for a significant reduction in the need for frequent infusions, e.g., potentially once a week for factor IX and twice a week for factor VIII.

Source: Seminars in Hematology - October 27, 2015 Category: Hematology Authors: Rajiv K Pruthi Source Type: research